Before heading out for Thanksgiving, our team took time to celebrate together with a little Friendsgiving fun. We’re grateful for the people who make Viridian such a special place to work! #TeamViridian #Thanksgiving #Gratitude
Viridian Therapeutics, Inc.
Biotechnology Research
Waltham, Massachusetts 19,634 followers
Framing the future of autoimmune diseases
About us
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
- Website
-
http://www.viridiantherapeutics.com
External link for Viridian Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Public Company
- Founded
- 2007
Locations
-
Primary
Get directions
203 Crescent St
Building 17, Suite 102B
Waltham, Massachusetts 02453, US
-
Get directions
6200 Lookout Road
Boulder, Colorado 80301, US
Employees at Viridian Therapeutics, Inc.
-
Thomas Martin
Commercial Operations | Life Sciences | Biotechnology | Go-to-Market Planning | Analytics | Brand Planning | Forecasting | Strategy | Program…
-
Nadezda Mitrovic, MD
Sr. Medical Director, Drug Safety and Pharmacovigilance @ Viridian Therapeutics | Board Certified Internal Medicine Specialist
-
Mark Howansky
Vice President of Device Development and Commercialization at Viridian Therapeutics, Inc.
-
Jon Sarno
Senior Director, Medical Device Quality at Viridian Therapeutics
Updates
-
November 10-16 has been designated Thyroid Eye Disease (TED) Awareness Week 2025! Join us in sharing daily facts to help increase visibility and understanding of TED and the effect it has on those living with this multidimensional autoimmune disease. Fact 5: Thyroid eye disease (TED) profoundly impacts multiple facets of daily life. Not only do people living with TED report issues with sleep, driving, reading, and working, but they often grapple with social isolation, anxiety, loss of self-confidence, and depression as well. Even though TED Awareness Week 2025 is coming to a close, we will continue to raise awareness and understanding of TED and the effect it has on those living with this multidimensional autoimmune disease all year long. Learn more about TED and check out our new “5 Things to Know About Thyroid Eye Disease” fact sheet over on https://lnkd.in/eEhSRyRg #TED #ThyroidEyeDisease #GravesDisease #Awareness #Autoimmune #Community #TEDAwarenessWeek
-
In recognition of Thyroid Eye Disease (TED) Awareness Week 2025 and our commitment to working alongside the community, we are sharing daily facts to increase visibility and understanding of TED. Fact 4: The way TED shows up may change over time. TED is typically described as having an initial active phase, followed by a chronic phase. - The active phase is characterized by inflammation and worsening of symptoms. - The chronic phase is associated with reduced inflammation. During this phase, physical changes to the eyes and face may remain. Some symptoms like double vision might also remain, while other symptoms stabilize or improve over time. There could also be periods within the chronic phase where people experience reactivation of inflammation and a flaring of symptoms. Learn more about TED and view our new “5 Things to Know About Thyroid Eye Disease” fact sheet over on https://lnkd.in/eEhSRyRg #TED #ThyroidEyeDisease #GravesDisease #Awareness #Autoimmune #Community #TEDAwarenessWeek
-
November 10-16 has been designated Thyroid Eye Disease (TED) Awareness Week 2025! Join us in sharing daily facts to help increase visibility and understanding of TED and the effect it has on those living with this multidimensional autoimmune disease. Fact 3: While not everyone living with TED will experience the same symptoms, the symptoms commonly associated with TED include – pain in, around, and behind the eyes; red and swollen eyes; dry, gritty eyes; sensitivity to light; excessive tearing; bulging of the eyes; and double vision. Learn more about TED by reading our new “5 Things to Know About Thyroid Eye Disease” fact sheet over on https://lnkd.in/eEhSRyRg #TED #ThyroidEyeDisease #GravesDisease #Awareness #Autoimmune #Community #TEDAwarenessWeek
-
November 10-16 has been designated Thyroid Eye Disease (TED) Awareness Week 2025! Join us in sharing daily facts to help increase visibility and understanding of TED and the effect it has on those living with this multidimensional autoimmune disease. Fact 2: Did you know that TED is often associated with other autoimmune diseases that affect the thyroid? For example, about 40% of people living with Graves’ disease also have TED. Given the close association, TED is also referred to as Graves’ eye disease, Graves’ ophthalmopathy, and Graves’ orbitopathy. Learn more about TED and view our new “5 Things to Know About Thyroid Eye Disease” fact sheet over on https://lnkd.in/eEhSRyRg #TED #ThyroidEyeDisease #GravesDisease #Awareness #Autoimmune #Community #TEDAwarenessWeek
-
For Thyroid Eye Disease (TED) Awareness Week 2025, we are sharing a daily fact to help raise awareness and deepen understanding of this complex autoimmune disease and its impact on those who live with it. Fact 1: TED is an autoimmune disease that occurs when the immune system mistakenly targets the tissue around and behind the eyes causing inflammation, growth, and damage. Learn more about TED and check out our new “5 Things to Know About Thyroid Eye Disease” fact sheet over on https://lnkd.in/eEhSRyRg #TED #ThyroidEyeDisease #GravesDisease #Awareness #Autoimmune #Community #TEDAwarenessWeek
-
Today is the start of Thyroid Eye Disease (TED) Awareness Week 2025! We are proud to work alongside Prevent Blindness and the broader community to raise awareness and drive progress forward for all living with TED. In addition to supporting various TED-focused events and activities throughout the week, we will also be sharing a new TED fact each day (Wednesday through Sunday) here on LinkedIn. Join us in bringing attention to TED by reposting these facts and by connecting with an advocacy organization to support their TED awareness activities. #TED #ThyroidEyeDisease #GravesDisease #Awareness #Autoimmune #Community #TEDAwarenessWeek
November 10-16 is Thyroid Eye Disease Week! Declared by Prevent Blindness, this week raises awareness about Thyroid Eye Disease (TED) - an autoimmune condition that can cause eye pain, irritation, redness, swelling, double vision, and bulging eyes. Risk factors include: - Age (most common in middle-aged adults) - Female gender - Family history of TED - Smoking 🚭 (increases risk 7–8x and can worsen symptoms) - Low selenium or vitamin D levels - Graves’ disease - Radioactive iodine therapy (used for hyperthyroidism) Prevent Blindness offers free, expert-approved TED resources - including fact sheets, videos, and social graphics in English and Spanish—to help individuals learn more and find support. #ThyroidEyeDisease #TEDWeek #EyeHealth #PreventBlindness TED Week is supported by funding from Amgen and Viridian Therapeutics, Inc.
-
This morning we announced our Q3 2025 results, reflecting a strong quarter highlighted by meaningful regulatory and clinical progress, key financing activities, and pipeline advancements that strengthen our position for future growth. Notable Highlights: 💠Submitted the veligrotug BLA to the U.S. FDA in October 2025. 💠Completed a comprehensive set of financing transactions in October 2025. 💠VRDN-003 REVEAL-1 and REVEAL-2 trials topline data readouts expected in Q1 and Q2 2026, respectively. 💠FcRn inhibitor portfolio continues to advance progress – proof-of-concept healthy volunteer data for VRDN-006 reported in Q3 2025; half-life extended VRDN-008 IND submission on track for year end 2025. Read more in our earnings release: https://lnkd.in/e6HQG9zg
-
-
We’re excited to share that we have successfully submitted our Biologics License Application (BLA) for veligrotug for the treatment of thyroid eye disease (#TED). We deeply appreciate the FDA’s continued support and collaboration to date, which enabled us to achieve this milestone despite the ongoing government shutdown. Read more: https://lnkd.in/eRarU_Hi
-
Our teams recently came together to celebrate #Diwali , the Festival of Lights, with a diya painting activity. It was a wonderful way to connect, create, and honor shared traditions! #CompanyCulture #TeamViridian